TITLE

BIOVAIL EXTENDS MARKETING PACT FOR ZOVIRAX OINTMENT/CREAM

PUB. DATE
February 2003
SOURCE
Worldwide Biotech;Feb2003, Vol. 15 Issue 2, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the extension of the marketing agreement between Biovail Corp. and GlaxoSmithKline Plc for the Zovirax (R) Ointment and Zovirax Cream, as of February 2003.
ACCESSION #
9014624

 

Related Articles

  • A tough pill to swallow. Sparks, Debra // Financial World;11/18/96, Vol. 165 Issue 14, p42 

    Questions the valuation of the stock of Biovail, which has launched the hypertension drug Tiazac. Institutional investors buying into the company; Competition posed by Cardizem, another drug; Consequences of the failure to genericize Procardia XL.

  • Canadian pharmaceutical to expand. Garza, Daniel R. // Caribbean Business;3/4/1999, Vol. 27 Issue 8, p2 

    Focuses on the additional employees projected by Biovail Corp. for its pharmaceutical manufacturing facility in Puerto Rico following the approval of its hypertension drug by the United States Food & Drug Administration (FDA).

  • FDA APPROVES BIOVAIL'S GENERIC PROCARDIA XL 30MG DOSAGE.  // Worldwide Biotech;Mar2001, Vol. 13 Issue 3, p1 

    Reports on the final approval granted by the United States Food and Drug Administration to Biovail Corporation's generic Procardia XL drug.

  • Forest to bid.  // Crain's New York Business;9/18/95, Vol. 11 Issue 38, p50 

    Reports on Forest Laboratories Inc.'s plan to announce a tender offer of 22% of Biovail Corp. International as part of a licensing agreement for Biovail's approved heart drug.

  • Biova Retains Ford Levine Sales Group.  // Nutraceuticals World;May2013, Vol. 16 Issue 4, p22 

    The article reports that the Ford Levine Sales Group for natural markets and international sales development has been retained by Biova Corp. in the U.S.

  • Biovale to provide 150 more jobs. Ruano, Lida Estela // Caribbean Business;12/28/1995, Vol. 23 Issue 52, p4 

    Reports that Biovale Corporation based in Canada, plans to develop a 150-job plant in Puerto Rico, which will produce products for sale in the United States market in the year 1997. Comments from Economic Development Administrator Jaime Morgan Stubbe.

  • BIOVAIL ACQUIRES MONOCOR MARKETING RIGHTS FOR CANADA.  // Worldwide Biotech;Apr2000, Vol. 12 Issue 4, p3 

    Reports that Biovail Corp. has acquired under license the exclusive market and distribution rights in Canada for Monocor, a cardio-selective beta-blocker for treatment of hypertension.

  • Short takes on high yields.  // High Yield Report;12/07/98, Vol. 9 Issue 47, p3 

    Presents news briefs related to the high yield investment market as of December 7, 1998. Includes Laclede Steel Co.'s filing of bankruptcy; Pressure to counter increased imports in the United States; Biovail Corp. International's denial of an intent to use proceeds of a junk offering to buyback...

  • Biovail reports record 1999 4th qtr/year-end results.  // Biotech Financial Reports;Apr2000, p2 

    Reports that Toronto, Ontario-based biotechnology company Biovail Corp. International has announced record earnings during the fourth quarter of 1999. Percentage increase in the company's earnings during the fourth quarter of 1999 as compared to that of the same period in 1998; Net income and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics